TCRT
Alaunos Therapeutics, Inc.NASDAQHealthcare$2.93-0.68%ClosedMarket Cap: $6.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.60
P/S
1281.07
EV/EBITDA
-1.19
DCF Value
$0.28
FCF Yield
-46.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
-84500.0%
Net Margin
-83520.0%
ROE
-172.7%
ROA
-140.8%
ROIC
-196.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $3.0K | 6100.0% | $-907.0K | $-893.0K | $-0.35 | — |
| FY 2025 | $5.0K | 0.0% | $-4.2M | $-4.2M | $-2.20 | — |
| Q3 2025 | $0.00 | NaN% | $-1.2M | $-1.2M | $-0.55 | — |
| Q2 2025 | $0.00 | -Infinity% | $-1.0M | $-1.1M | $-0.63 | — |
| Q1 2025 | $2.0K | 100.0% | $-1.1M | $-1.1M | $-0.67 | — |
| Q4 2024 | $4.0K | 100.0% | $-755.0K | $-742.0K | $-0.46 | — |
| FY 2024 | $10.0K | 100.0% | $-4.8M | $-4.7M | $-2.92 | — |
| Q3 2024 | $0.00 | NaN% | $-1.1M | $-1.1M | $-0.70 | — |
| Q2 2024 | $4.0K | -4400.0% | $-1.2M | $-1.1M | $-0.71 | — |
| Q1 2024 | $1.0K | -100.0% | $-1.7M | $-1.7M | $-1.05 | — |
| Q4 2023 | $1.0K | -93200.0% | $-7.9M | $-7.8M | $-4.90 | — |
| FY 2023 | $5.0K | -95960.0% | $-34.3M | $-35.1M | $-21.97 | — |